Skip to main content
Erschienen in: Journal of Neurology 10/2016

02.08.2016 | Original Communication

Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain–Barré syndrome

verfasst von: L. Schirmer, V. Worthington, U. Solloch, V. Loleit, V. Grummel, N. Lakdawala, D. Grant, R. Wassmuth, A. H. Schmidt, F. Gebhardt, T. F. M. Andlauer, J. Sauter, A. Berthele, M. P. Lunn, Bernhard Hemmer

Erschienen in: Journal of Neurology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Few regional and seasonal Guillain–Barré syndrome (GBS) clusters have been reported so far. It is unknown whether patients suffering from sporadic GBS differ from GBS clusters with respect to clinical and paraclinical parameters, HLA association and antibody response to glycosphingolipids and Campylobacter jejuni (Cj). We examined 40 consecutive patients with GBS from the greater Munich area in Germany with 14 of those admitted within a period of 3 months in fall 2010 defining a cluster of GBS. Sequencing-based HLA typing of the HLA genes DRB1, DQB1, and DPB1 was performed, and ELISA for anti-glycosphingolipid antibodies was carried out. Clinical and paraclinical findings (Cj seroreactivity, cerebrospinal fluid parameters, and electrophysiology) were obtained and analyzed. GBS cluster patients were characterized by a more severe clinical phenotype with more patients requiring mechanical ventilation and higher frequencies of autoantibodies against sulfatide, GalC and certain ganglioside epitopes (54 %) as compared to sporadic GBS cases (13 %, p = 0.017). Cj seropositivity tended to be higher within GBS cluster patients (69 %) as compared to sporadic cases (46 %, p = 0.155). We noted higher frequencies of HLA class II allele DQB1*05:01 in the cluster cohort (23 %) as compared to sporadic GBS patients (3 %, p = 0.019). Cluster of severe GBS was defined by higher frequencies of autoantibodies against glycosphingolipids. HLA class II allele DQB1*05:01 might contribute to clinical worsening in the cluster patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Hadden RD, Karch H, Hartung HP et al (2001) Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 56:758–765CrossRefPubMed Hadden RD, Karch H, Hartung HP et al (2001) Preceding infections, immune factors, and outcome in Guillain–Barré syndrome. Neurology 56:758–765CrossRefPubMed
3.
4.
Zurück zum Zitat van Koningsveld R, Schmitz PIM, Ang CW et al (2002) Infections and course of disease in mild forms of Guillain–Barré syndrome. Neurology 58:610–614CrossRefPubMed van Koningsveld R, Schmitz PIM, Ang CW et al (2002) Infections and course of disease in mild forms of Guillain–Barré syndrome. Neurology 58:610–614CrossRefPubMed
11.
Zurück zum Zitat Kusunoki S, Shiina M, Kanazawa I (2001) Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57:736–738CrossRefPubMed Kusunoki S, Shiina M, Kanazawa I (2001) Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57:736–738CrossRefPubMed
12.
Zurück zum Zitat Ang CW, Tio-Gillen AP, Groen J et al (2002) Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain–Barré syndrome. J Neuroimmunol 130:179–183CrossRefPubMed Ang CW, Tio-Gillen AP, Groen J et al (2002) Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain–Barré syndrome. J Neuroimmunol 130:179–183CrossRefPubMed
13.
Zurück zum Zitat Ogawara K, Kuwabara S, Mori M et al (2000) Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48:624–631CrossRefPubMed Ogawara K, Kuwabara S, Mori M et al (2000) Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48:624–631CrossRefPubMed
15.
Zurück zum Zitat Adams D, Gibson JD, Thomas PK et al (1977) HLA antigens in Guillain–Barré syndrome. Lancet 2:504–505CrossRefPubMed Adams D, Gibson JD, Thomas PK et al (1977) HLA antigens in Guillain–Barré syndrome. Lancet 2:504–505CrossRefPubMed
17.
19.
Zurück zum Zitat Rees JH, Vaughan RW, Kondeatis E, Hughes RA (1995) HLA-class II alleles in Guillain–Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 62:53–57CrossRefPubMed Rees JH, Vaughan RW, Kondeatis E, Hughes RA (1995) HLA-class II alleles in Guillain–Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 62:53–57CrossRefPubMed
20.
Zurück zum Zitat Magira EE, Papaioakim M, Nachamkin I et al (2003) Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain–Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 170:3074–3080CrossRefPubMed Magira EE, Papaioakim M, Nachamkin I et al (2003) Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain–Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 170:3074–3080CrossRefPubMed
21.
Zurück zum Zitat Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753CrossRefPubMed Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2:750–753CrossRefPubMed
22.
Zurück zum Zitat van Koningsveld R, van Doorn PA, Schmitz PI et al (2000) Mild forms of Guillain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54:620–625CrossRefPubMed van Koningsveld R, van Doorn PA, Schmitz PI et al (2000) Mild forms of Guillain–Barré syndrome in an epidemiologic survey in The Netherlands. Neurology 54:620–625CrossRefPubMed
23.
Zurück zum Zitat Guillain–Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain–Barré syndrome. Lancet 341:586–590. doi:10.1016/0140-6736(93)90351-G Guillain–Barré Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain–Barré syndrome. Lancet 341:586–590. doi:10.​1016/​0140-6736(93)90351-G
24.
Zurück zum Zitat Willison HJ, Veitch J, Swan AV et al (1999) Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 6:71–77CrossRefPubMed Willison HJ, Veitch J, Swan AV et al (1999) Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 6:71–77CrossRefPubMed
27.
28.
Zurück zum Zitat Merkies ISJ, Schmitz PIM, Van der Meché FGA et al (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatr 72:596–601CrossRefPubMedPubMedCentral Merkies ISJ, Schmitz PIM, Van der Meché FGA et al (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatr 72:596–601CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Hadden RD, Cornblath DR, Hughes RA et al (1998) Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 44:780–788. doi:10.1002/ana.410440512 CrossRefPubMed Hadden RD, Cornblath DR, Hughes RA et al (1998) Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome Trial Group. Ann Neurol 44:780–788. doi:10.​1002/​ana.​410440512 CrossRefPubMed
31.
Zurück zum Zitat Allos BM (1997) Association between Campylobacter infection and Guillain–Barré syndrome. J Infect Dis 176(Suppl 2):S125–S128CrossRefPubMed Allos BM (1997) Association between Campylobacter infection and Guillain–Barré syndrome. J Infect Dis 176(Suppl 2):S125–S128CrossRefPubMed
32.
Zurück zum Zitat Schmidt AH, Baier D, Solloch UV et al (2009) Estimation of high-resolution HLA-A, -B, -C, -DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70:895–902. doi:10.1016/j.humimm.2009.08.006 CrossRefPubMed Schmidt AH, Baier D, Solloch UV et al (2009) Estimation of high-resolution HLA-A, -B, -C, -DRB1 allele and haplotype frequencies based on 8862 German stem cell donors and implications for strategic donor registry planning. Hum Immunol 70:895–902. doi:10.​1016/​j.​humimm.​2009.​08.​006 CrossRefPubMed
33.
Zurück zum Zitat Enders U, Karch H, Toyka KV et al (1993) The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain–Barré syndrome and in other neuroimmunological disorders. Ann Neurol 34:136–144. doi:10.1002/ana.410340208 CrossRefPubMed Enders U, Karch H, Toyka KV et al (1993) The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain–Barré syndrome and in other neuroimmunological disorders. Ann Neurol 34:136–144. doi:10.​1002/​ana.​410340208 CrossRefPubMed
34.
Zurück zum Zitat Jacobs BC, Rothbarth PH, van der Meché FG et al (1998) The spectrum of antecedent infections in Guillain–Barré syndrome: a case–control study. Neurology 51:1110–1115CrossRefPubMed Jacobs BC, Rothbarth PH, van der Meché FG et al (1998) The spectrum of antecedent infections in Guillain–Barré syndrome: a case–control study. Neurology 51:1110–1115CrossRefPubMed
35.
Zurück zum Zitat Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36:123–133. doi:10.1159/000324710 CrossRefPubMed Sejvar JJ, Baughman AL, Wise M, Morgan OW (2011) Population incidence of Guillain–Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36:123–133. doi:10.​1159/​000324710 CrossRefPubMed
36.
Zurück zum Zitat Chiba A, Kusunoki S, Obata H et al (1993) Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology 43:1911–1917CrossRefPubMed Chiba A, Kusunoki S, Obata H et al (1993) Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology 43:1911–1917CrossRefPubMed
37.
38.
Zurück zum Zitat Lopate G, Pestronk A, Kornberg AJ et al (1997) IgM anti-sulfatide autoantibodies: patterns of binding to cerebellum, dorsal root ganglion and peripheral nerve. J Neurol Sci 151:189–193CrossRefPubMed Lopate G, Pestronk A, Kornberg AJ et al (1997) IgM anti-sulfatide autoantibodies: patterns of binding to cerebellum, dorsal root ganglion and peripheral nerve. J Neurol Sci 151:189–193CrossRefPubMed
39.
Zurück zum Zitat Carpo M, Meucci N, Allaria S et al (2000) Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 176:144–150CrossRefPubMed Carpo M, Meucci N, Allaria S et al (2000) Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci 176:144–150CrossRefPubMed
40.
Zurück zum Zitat van den Berg LH, Lankamp CL, de Jager AE et al (1993) Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatr 56:1164–1168CrossRefPubMedPubMedCentral van den Berg LH, Lankamp CL, de Jager AE et al (1993) Anti-sulphatide antibodies in peripheral neuropathy. J Neurol Neurosurg Psychiatr 56:1164–1168CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ilyas AA, Mithen FA, Dalakas MC et al (1991) Antibodies to sulfated glycolipids in Guillain–Barré syndrome. J Neurol Sci 105:108–117CrossRefPubMed Ilyas AA, Mithen FA, Dalakas MC et al (1991) Antibodies to sulfated glycolipids in Guillain–Barré syndrome. J Neurol Sci 105:108–117CrossRefPubMed
44.
Zurück zum Zitat Tautz C, Rihs HP, Thiele A et al (1994) Association of class II sequences encoding DR1 and DQ5 specificities with hypersensitivity to chironomid allergen Chi t I. J Allergy Clin Immunol 93:918–925CrossRefPubMed Tautz C, Rihs HP, Thiele A et al (1994) Association of class II sequences encoding DR1 and DQ5 specificities with hypersensitivity to chironomid allergen Chi t I. J Allergy Clin Immunol 93:918–925CrossRefPubMed
Metadaten
Titel
Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain–Barré syndrome
verfasst von
L. Schirmer
V. Worthington
U. Solloch
V. Loleit
V. Grummel
N. Lakdawala
D. Grant
R. Wassmuth
A. H. Schmidt
F. Gebhardt
T. F. M. Andlauer
J. Sauter
A. Berthele
M. P. Lunn
Bernhard Hemmer
Publikationsdatum
02.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 10/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-016-8237-6

Weitere Artikel der Ausgabe 10/2016

Journal of Neurology 10/2016 Zur Ausgabe

Pioneers in Neurology

Georges Guillain (1876–1961)

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.